RTRX - Retrophin, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
21.11
-0.28 (-1.31%)
As of 1:34PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close21.39
Open21.40
Bid21.12 x 800
Ask21.14 x 1200
Day's Range20.83 - 21.77
52 Week Range17.53 - 33.00
Volume299,765
Avg. Volume427,327
Market Cap874.788M
Beta (3Y Monthly)0.72
PE Ratio (TTM)N/A
EPS (TTM)-3.07
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est43.43
Trade prices are not sourced from all markets
  • Analysts Estimate Retrophin (RTRX) to Report a Decline in Earnings: What to Look Out for
    Zacksyesterday

    Analysts Estimate Retrophin (RTRX) to Report a Decline in Earnings: What to Look Out for

    Retrophin (RTRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Benzinga20 days ago

    The Week Ahead In Biotech: Pending Clinical Readouts In Focus

    Biotech stocks headed south last week, reversing decent gains made in the previous week. Unfavorable FDA decisions, botched trials and weaker broader market sentiment all weighed down on the sector. Here ...

  • U.S. court urged to throw out 'Pharma Bro' Martin Shkreli's conviction
    Reuters21 days ago

    U.S. court urged to throw out 'Pharma Bro' Martin Shkreli's conviction

    A lawyer for former pharmaceutical executive Martin Shkreli on Friday urged a federal appeals court to overturn Shkreli's criminal conviction for defrauding investors in hedge funds he founded. The lawyer, Mark Baker, argued that the jury that convicted Shkreli was given incorrect instructions about securities fraud. Baker faced a barrage of skeptical questions from a three-judge panel during a brief proceeding in the 2nd U.S. Circuit Court of Appeals in Manhattan.

  • An Intrinsic Calculation For Retrophin, Inc. (NASDAQ:RTRX) Suggests It's 36% Undervalued
    Simply Wall St.24 days ago

    An Intrinsic Calculation For Retrophin, Inc. (NASDAQ:RTRX) Suggests It's 36% Undervalued

    How far off is Retrophin, Inc. (NASDAQ:RTRX) from its intrinsic value? Using the most recent financial data, we'll...

  • Is Retrophin, Inc. (NASDAQ:RTRX) Trading At A 36% Discount?
    Simply Wall St.24 days ago

    Is Retrophin, Inc. (NASDAQ:RTRX) Trading At A 36% Discount?

    In this article we are going to estimate the intrinsic value of Retrophin, Inc. (NASDAQ:RTRX) by taking the expected...

  • Shkreli and Retrophin resolve 'all outstanding disputes'
    American City Business Journals28 days ago

    Shkreli and Retrophin resolve 'all outstanding disputes'

    A Retrophin spokeswoman confirmed Thursday that the settlement covers Shkreli’s $30 million lawsuit from last month.

  • Martin Shkreli settles all litigation with his former company Retrophin
    Reuters29 days ago

    Martin Shkreli settles all litigation with his former company Retrophin

    Martin Shkreli, the pharmaceutical entrepreneur serving a seven-year prison term for fraud, has settled all outstanding disputes with Retrophin Inc, the biopharmaceutical company he founded in 2011 and which ousted him three years later. A Retrophin spokeswoman said on Thursday that the accord covers Shkreli's $30 million lawsuit last month accusing three former colleagues, including his successor as chief executive, of engineering his ouster and to enrich themselves from his work. The settlement also covers claims Retrophin first raised in August 2015, in a $65 million lawsuit accusing Shkreli of repeatedly breaching his duty of loyalty to the San Diego-based company.

  • GlobeNewswirelast month

    Retrophin Announces Cooperative Research and Development Agreement with NCATS and the Alagille Syndrome Alliance to Identify Potential Therapeutics for Alagille Syndrome

    Retrophin, Inc. (RTRX) today announced that it has entered into a three-way Cooperative Research and Development Agreement (CRADA) with the National Institutes of Health’s National Center for Advancing Translational Sciences (NCATS) and patient advocacy foundation Alagille Syndrome Alliance (ALGSA) to collaborate on research efforts aimed at the identification and development of potentially novel therapeutics for Alagille syndrome (ALGS). ALGS is a rare and debilitating disease characterized by severe liver and cardiovascular abnormalities.

  • Is Retrophin, Inc.'s (NASDAQ:RTRX) Balance Sheet A Threat To Its Future?
    Simply Wall St.2 months ago

    Is Retrophin, Inc.'s (NASDAQ:RTRX) Balance Sheet A Threat To Its Future?

    While small-cap stocks, such as Retrophin, Inc. (NASDAQ:RTRX) with its market cap of US$768m, are popular for their...

  • From prison, 'Pharma Bro' Martin Shkreli sues ex-colleagues for $30 million
    Reuters2 months ago

    From prison, 'Pharma Bro' Martin Shkreli sues ex-colleagues for $30 million

    Martin Shkreli, the pharmaceutical entrepreneur serving a seven-year prison term for fraud, on Friday sued three former colleagues at Retrophin Inc for more than $30 million, saying they illegally ousted him from that company in 2014. In a complaint filed in Manhattan federal court, Shkreli said Stephen Aselage, Margaret Valeur-Jensen and Gary Lyons fraudulently induced him to negotiate his exit from Retrophin, only to then "trick him" into signing away his rights as chief executive and founder without receiving anything in return. Shkreli said the defendants were "driven by their egos, jealousy, and greed," and that Aselage and Valeur-Jensen then "paid themselves" more than $35 million from assets he created.

  • CNBC2 months ago

    'Pharma bro' Martin Shkreli sues Retrophin directors, ex-general counsel for more than $30 million from prison in Pennsylvania

    Notorious 'pharma bro' Martin Shkreli is sued two directors and the ex-general counsel of his former biopharmaceutical company Retrophin for more than $30 million, accusing them of using fraud to oust him as head of the firm in 2014. It was lodged within days of him being transferred to a new prison in Pennsylvania, where he will continue serving a seven-year sentence for securities fraud related to Retrophin and two hedge funds, which financially collapsed under his operation. Shkreli gained national infamy in 2015 after his Turing Pharmaceuticals, now known as Phoenixus AG, hiked the price of its drug Daraprim by more than 5,000%.

  • GlobeNewswire2 months ago

    Retrophin to Present at Upcoming Investor Conferences

    SAN DIEGO, May 30, 2019 -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Company management will present at the following upcoming investor conferences in June:.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of RTRX earnings conference call or presentation 7-May-19 8:30pm GMT

    Q1 2019 Retrophin Inc Earnings Call

  • GlobeNewswire2 months ago

    Retrophin Appoints Sandra E. Poole to Board of Directors

    Retrophin, Inc. (RTRX) today announced the appointment of Sandra E. Poole to the Company's Board of Directors, effective immediately. Ms. Poole brings more than 25 years of biopharmaceutical industry experience in manufacturing strategy, including chemistry, manufacturing and controls (CMC), technical operations, and product development from research through commercialization.

  • Retrophin (RTRX) Q1 2019 Earnings Call Transcript
    Motley Fool2 months ago

    Retrophin (RTRX) Q1 2019 Earnings Call Transcript

    RTRX earnings call for the period ending March 31, 2019.

  • Retrophin (RTRX) Reports Q1 Loss, Misses Revenue Estimates
    Zacks2 months ago

    Retrophin (RTRX) Reports Q1 Loss, Misses Revenue Estimates

    Retrophin (RTRX) delivered earnings and revenue surprises of -75.00% and -5.72%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    Retrophin: 1Q Earnings Snapshot

    On a per-share basis, the San Diego-based company said it had a loss of 99 cents. Losses, adjusted for non-recurring costs and stock option expense, came to 63 cents per share. The drug developer posted ...

  • GlobeNewswire2 months ago

    Retrophin Reports First Quarter 2019 Financial Results

    Top-line results from pivotal Phase 3 FORT Study in PKAN on-track for 3Q 2019 Enrollment ongoing in Phase 3 clinical trials of sparsentan for patients with rare nephropathies.

  • ACCESSWIRE2 months ago

    Retrophin, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 7, 2019 / Retrophin, Inc. (NASDAQ: RTRX ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 7, 2019 at 4:30 PM Eastern Time. ...

  • Here’s What Hedge Funds Think About Retrophin Inc (RTRX)
    Insider Monkey2 months ago

    Here’s What Hedge Funds Think About Retrophin Inc (RTRX)

    Looking for stocks with high upside potential? Just follow the big players within the hedge fund industry. Why should you do so? Let’s take a brief look at what statistics have to say about hedge funds’ stock picking abilities to illustrate. The Standard and Poor’s 500 Index returned approximately 13.1% in the 2.5 months of 2019 (including […]

  • 2 Healthcare Stocks With Jaw-Dropping Growth Potential
    Motley Fool3 months ago

    2 Healthcare Stocks With Jaw-Dropping Growth Potential

    These two growth stocks are poised for enormous gains.

  • The Retrophin (NASDAQ:RTRX) Share Price Is Up 41% And Shareholders Are Holding On
    Simply Wall St.3 months ago

    The Retrophin (NASDAQ:RTRX) Share Price Is Up 41% And Shareholders Are Holding On

    It might be of some concern to shareholders to see the Retrophin, Inc. (NASDAQ:RTRX) share price down 13% in the last month. In contrast the stock is up over the last three years. In that time, it is up 41%, which isn...

  • GlobeNewswire3 months ago

    Retrophin to Report First Quarter 2019 Financial Results

    SAN DIEGO, April 23, 2019 -- Retrophin, Inc. (NASDAQ: RTRX) today announced it will report first quarter 2019 financial results on Tuesday, May 7, 2019 after the close of the.